Partnerships

Bringing diagnostic testing for a variety of applications to the people that need it most

The world has become aware of the power of testing as a tool to access critical information about personal health. Sherlock is driving the future of molecular diagnostics. Partner with us to advance the development and adoption of novel diagnostic platforms for virtually any setting.

Development Partnerships

Looking for rapid, field testing of nucleic acid targets? Sherlock’s advanced CRISPR-based chemistries are highly programmable and portable onto Sherlock’s low-cost devices, or on partners’ point-of-care platforms.

Sherlock’s platform is the ultimate near-patient solution for molecular diagnostics, in applications ranging from pathogen detection to RNA markers of disease for cancer screening or therapy monitoring. It also uniquely suited for field testing of pathogens affecting livestock, crops, or food supply chains.

Brand Partnerships

Consumer demand for highly accurate, fast and affordable diagnostic tests is rising. Sherlock’s novel molecular diagnostic platform brings together the lab-level accuracy of PCR with the convenience and simplicity of disposable antigen tests, providing a powerful consumer solution.

We offer consumer OTC brands the ability to bolster their existing solutions or accelerate their innovation pipeline by licensing our technology to use in their consumer offerings. This provides a competitive advantage to brands operating in the crowded consumer health market.

Global Health Partnerships

Through our 221b Foundation we are further committed to developing, producing, and distributing easy to use and affordable diagnostics for infectious diseases afflicting countries in the developing world. Contact us to discuss global health partnerships.

Sherlock™ CRISPR-based chemistry is approved for clinical laboratory use

The Sherlock™ CRISPR-based SARS-CoV-2 kit was the very first FDA authorized CRISPR-based EUA diagnostic test for use in clinical laboratory settings

The Sherlock™ CRISPR-based SARS-CoV-2 kit is intended for the qualitative detection of nucleic acid from SARS-CoV-2. This test provides specific and sensitive detection of the SARS-CoV-2 virus in upper respiratory tract and bronchoalveolar lavage specimens from individuals suspected of COVID-19 by their healthcare provider.

Benefits

Faster than PCR; approximately 1 hour reaction time

Add thousands of tests per day to current lab volume

Highly specific and sensitive as demonstrated in EUA clinical evaluation and subsequent publication

Minimal footprint; uses standard laboratory equipment and a microplate reader

Proven highly sensitive with Limit of Detection comparable to RT-PCR

Safety, Legal, Quality, Usage Publications

More Info

Instructions for Use Our FAQ Fact Sheet for Healthcare Providers Fact Sheet for Patients

This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.